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Abstract  
Numerous studies have attempted to demonstrate the olfactory ability of canines to detect several 
common cancer types from human bodily fluids, breath and tissue. Canines have been reported to 
detect bladder cancer (sensitivity of 0.63-0.73 and specificity of 0.64-0.92) and prostate cancer 
(sensitivity of 0.91-0.99 and specificity of 0.91-0.97) from urine; breast cancer (sensitivity of 0.88 and 
specificity of 0.98) and lung cancer (sensitivity 0.56-0.99 and specificity of 8.30-0.99) on breath and 
colorectal cancer from stools (sensitivity of 0.91-0.97 and specificity of 0.97-0.99). The quoted figures 
of sensitivity and specificity across differing studies demonstrate that in many cases results are 
variable from study to study; this raises questions about the reproducibility of methodology and study 
design which we have identified herein. Furthermore in some studies the controls used have resulted 
in differentiation of samples which are of limited use for clinical diagnosis.  
These studies provide some evidence that cancer gives rise to different volatile organic compounds 
(VOCs) compared to healthy samples. Whilst canine detection may be unsuitable for clinical 
implementation they can, at least, provide inspiration for more traditional laboratory investigations.  
 
Introduction  
The olfactory ability of canines has long been recognised, and this ability has been exploited by 
humans for centuries e.g. bloodhounds for tracking people and animals. Since the on-set of World 
War II canines have been utilized to detect explosives, due in no small part to their rapid detection 
capabilities (Furton and Myers, 2001). Humans are estimated to have between 650 and 900 olfactory 
receptor genes, the canine genome contains an estimated 1300 (Quignon et al, 2005). While this 
difference does not at first inspection appear highly significant the human receptor gene repertoire is 
thought to contain a significantly higher proportion of pseudogenes compared to that of canines. As a 
result the human nose is thought to contain approximately 5 million olfactory receptors, whilst a 
canine nose is thought to contain in excess of forty times this figure (Lippi and Cervellin, 2012).  
The use of canines for disease detection is a relatively new phenomenon. It is often cited that the first 
report of a canine’s ability to ‘detect’ cancer was a letter to the Lancet from William and Pembroke 
(1989) which details the anecdotal account of a woman whose pet obsessed over a skin lesion, 
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prompting her to seek medical attention. The lesion was later found to be a melanoma. Since then 
research into the area of disease detection by canines has rapidly expanded and scientists have 
attempted to rigorously test the olfactory ability of canines and other animals to detect odours 
associated with cancer. An early review by Moser and McCulloch (2010) provides an in-depth 
description and discussion of such studies, but is now outdated due to the rapidly expanding nature of 
this field. A later review by Bijland et al. (2013) broadly describes olfactory detection of disease by 
animals, although does not describe the field of canine detection comprehensively.  
Recently, studies using canines to detect the infectious pathogenic Clostridium difficile in hospitals 
have received publicity. Canines have also been reported to have detected the gastrointestinal 
bacterial infection from stool samples with very high sensitivity and specificity (Bomers et al. 2012 and 
2014), and have the advantage of being much quicker than current conventional methods (cytotoxin 
assay results take 1-2 days). This result is currently superior to that achieved by a prototype gas 
chromatography-gas sensor system (McGuire et al, 2014). Medical detection dogs have also been 
trained to sense oncoming hypoglycaemic episodes – a dangerous complication affecting those living 
with diabetes. It has been hypothesised canines can react to olfactory cues from changes in blood 
sugar levels; as the canines were able to alert their owners to hypo/hyper-glycaemic episodes even 
during sleep (Rooney et al, 2013).  
In the western world, cancer is a growing problem probably due to an ageing population, which is not 
only of great cost to individuals, but puts a financial strain on healthcare services.  Cancer prognosis 
and survival rates largely depend on the stage at which it is detected, with early diagnosis allowing 
more treatment options and better outcomes (Cancer Research UK, 2014). Where routine screening 
is available e.g. for breast (mammograms) and cervical cancer (smear tests) prognosis has drastically 
improved; however there are insufficient screening options available in most cases. To be effective, 
diagnostic tests must meet certain criterion including a need for high sensitivity and specificity. 
Additionally tests of this nature must be cost effective (cost of testing to incidence of disease ratio), 
provide high positive predictive values (PPV) and negative predictive values (NPV), ideally yield a 
rapid result, and biomarkers should correlate with disease progression and regression.  
This field inspires many applications, namely the non-invasive screening of cancer using breath, 
urine, faeces etc. Whilst canines in a clinical setting may be impractical, by identifying the important 
compounds that canines can detect, there is the potential to optimise sampling methods and 
analytical techniques of these compounds with a view to developing the potential use of non-invasive 
biomarkers. There is also potential in the shorter term that canines could provide a service in second 
line screening where samples are brought to a canine in a separate location similar to the government 
licensed DSTL RASCargO™ system for explosive detection (Wickens, 2001). It should be highlighted 
though, that whilst some studies support the use of canines in detecting odours associated with 
cancers there are often large discrepancies between studies. For instance Ehmann et al (2012) 
investigating lung cancer reported sensitivity of 0.71 and specificity of 0.93. Two years later 
Amundson et al (2014) also investigating lung cancer reported sensitivities ranging from 0.62 to 0.65 
and specificities from 0.08 to 0.16. Moreover there are inconsistencies in the methodologies used 
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across the field (Moser and McCulloch, 2010). Here we aim to discuss both the advantages of canine 
detection and the shortcomings that need to be addressed such as sample collection methods and 
study design.  
Method 
Our research  
Google scholar and pub med search engines were utilised for this paper. A number of combinations 
of keywords were used. The keywords were:- canine, dog, olfactory, smell, sniff, scent, detection, 
diagnosis, cancer, training, methods, disease, breath, urine, faeces, stool, bladder, breast, colorectal, 
lung, melanoma, prostate, ovarian, analysis, gas chromatography, mass spectrometry and volatile 
organic compounds (VOCs).  In addition papers were also found via manual search, for example in 
the references of other relevant papers. 
Typical canine training and testing methodology  
Canines are trained using a reward-based system, usually food or a toy (McCulloch et al, 2006, 
Sonoda et al, 2011). The overall training duration and intensity of training varies a between studies. 
For instance Cornu et al (2011) spent 5 days a week over a 16 month period on training; whist 
Sonoda et al (2011) conducted their study over an 8 month period some 3 years after training began. 
Over the three year training period the canine was conditioned to detect a range of cancers including 
(but not exclusively): gastric cancer, lung cancer, breast cancer and colorectal cancer; all training was 
performed with breath samples, controls (n=500) were obtained by internet advertisement. It is worth 
noting the amount of cancerous samples used over this timeframe was not stated and nor was the 
frequency with which training sessions took place. A number of the reviewed studies do not report the 
duration of training (such as Ehmann et al (2012) and McCulloch et al (2006)). Training is often 
continued throughout the study duration as in Amundson et al, 2014 who maintained two training 
sessions per week, following low initial accuracy this training increased to four sessions per week. 
The test procedure usually takes place in a bare, familiar room (fewer distractions) with/without an 
observer present. These rooms usually (though not exclusively) share characteristics such as vinyl 
tiling, fluorescent lighting, no climate control, and some natural light (McColloch et al, 2006 and 
Sonoda et al, 2011).   Cancerous samples and control samples are normally arranged in containers 
on the floor or in a carousel; canines (and their handlers) then enter the room and sniff each one in 
turn. It is noteworthy that of the reviewed literature the rational behind selection of the training and 
testing methodology employed (e.g. number of samples presented and use of carousel versus 
containers) is often not alluded to. The number of samples presented to the canine at any one time 
also varies between studies. Of the 14 papers reviewed the lowest number of samples in a test was 5 
(4 control and one cancerous) (Rudnicka et al, 2014) and the highest 10 (8 control and 2 cancerous) 
(Horvath et al, 2010); though only 2 of the studies presented the canines with more than 6 samples at 
one time. Canines indicate (often by sitting in front of it (Ehmann et al, 2012)) which sample they 
believe has a differing odour pattern. A double blind study design was the most common amongst the 
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studies reviewed (10 out of 13), 1 conducted both single and double blind tests; while 1 only 
conducted a single blind study. 1 paper did not indicate the study design employed (see Table 1.1). 
The double blind design ensures there are no conscious or subconscious indicators by the handler or 
laboratory assist (if used) to assist the canine performance (McCulloch et al, 2006). 
Results and discussion 
Bladder cancer  
An early pilot study by Willis et al. (2004) trained 6 canines (of different breeds, not specified) over 7 
months to distinguish between bladder cancer and control urine. 36 Patients with bladder cancer and 
108 controls (either healthy or with benign disease) were used, 9 Cancer samples and 54 control 
samples were used for formal testing, with the remaining 27 patient samples and 54 controls used 
during the training period. Air-dried urine and liquid urine (previously frozen at -40oC for up to 5 
months and thawed) were used in separate tests. The canines had an overall mean success rate of 
41% for dried and liquid urine tests combined, performing significantly better than chance (14% 
expected, based on 1 in 7 random chance of success as 1 cancerous and 6 control samples were 
used per test) in single blind tests. Dried urine sample testing could only achieve a 22% success rate 
compared to the 50% for liquid urine. There is no indication that the same canine was used for both a 
liquid and dried sample, this step could have aided in drawing possible conclusions on the handling 
and storage of urine samples for volatile organic compound (VOC) analysis. In each test one 
cancerous sample and six controls were used, one control for each test was age matched (some tests 
had two age matched controls); the age matched controls also had a non-cancerous urological 
pathology as did two non-age matched controls, the remaining control samples were from healthy 
participants. Control samples were sex matched to prevent hormonal interference.  
Willis et al. (2011) later trained 4 canines of unspecified breeds to distinguish between bladder cancer 
urine and control urine. Urine samples were refrigerated within 45 minutes of collection, and then 
frozen at -80oC until needed (up to six months). Using a double blind study, a sensitivity of 0.73 was 
obtained (from the best canine), though the group as a whole only obtained a sensitivity of 0.64. 
Specificity was reportedly 0.92 when cancerous urine was compared to urine from young, healthy 
controls; but a decrease in performance was seen when control urine was taken from elderly 
individuals with other benign urological diseases (specificity down to 0.56). This wide variation is 
suggestive that other alterations to urine odour patterns, due to age and other urological conditions 
can greatly reduce the efficiency of the canine ability to recognise specific cancer odour patterns. This 
highlights the need to select appropriate controls, this problem is not unique to canine studies a 
number analytical models also note drops in performance when age and symptom matched controls 
are introduced. The above results were generated from 210 participants, these were divided into 4 
groups, control group 1 (n=61) were all younger than 33 and were healthy, control group 2 (n=65) had 
any non-cancerous and non-urological disease though did show abnormal urine, control group 3 
(n=54) were a range of ages with benign urological diseases e.g. benign prostatic hyperplasia. 119 of 
the total participants were female, the remaining 91 were male. The remaining 30 participants all had 
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confirmed transitional cell carcinoma. This paper does go into considerable detail of the participants 
involved and the clinical findings of each; it is not a common feature amongst the papers reviewed, to 
report in such detail on the controls samples used. None of the samples (patient or controls) were 
used during the training phase, the sample collection and storage of samples used in training was not 
commented upon.    
Some work has been carried out to use sensors in an attempt to identify the VOC patterns associated 
with bladder cancer. Weber et al, (2011) used a gas sensor array in conjunction with pattern 
recognition software, to identify patients with bladder cancer. Although a small sample size was 
obtained the figures suggest further merit to the hypothesis that VOC differences can be associated 
with bladder cancer. In this instance 30 patient samples with new or recurrent bladder carcinoma 
were used. The control samples were comprised of three groups: 1) 20 healthy individuals, 2) 20 any 
non-cancer diseased patients, and 3) 19 non-cancer urological diseased patients. Urine samples 
were refrigerated immediately following collection then frozen at -80oC; when needed these were then 
thawed and incubated at 380C. This same procedure of utilising urine samples is also commonplace 
amongst canine studies. This team found despite the presence of other non-cancerous urological 
disease in the controls, a sensitivity of 60% and specificity of 67%. Another group, Khalid et al, 2013 
using a gas chromatography (GC) - sensor system with a statistical model, in a similar pilot study also 
had significant success in identifying VOC patterns in patients with bladder cancer. This modestly 
sized study of 98 participants, 24 with confirmed bladder cancer, and 74 control participants, had all 
undergone assessment for urological symptoms (e.g. haematuria) yielding a 95.8% leave-one-out 
cross-validation prediction value. Urine samples were stored at -20oC and defrosted by immersion in 
an 80oC water bath before the headspace was sampled with a Hamilton gas syringe. Whilst neither of 
these approaches identified the potential biomarker compounds responsible for the observed 
differences they indicate further investigation into odour patterns in the urine of bladder cancer 
patients is warranted.  
Breast Cancer  
Breast cancer is the commonest cancer among women in the UK (Cancer Research UK, 2014). 
Routine screening is already in place for breast cancer in the form of mammograms, which have 
greatly improved prognosis by encouraging early detection. However, mammograms are only offered 
to women over the age of 50 and therefore do not improve early diagnosis in younger women, and 
there has been some criticism that mammograms may lead to over diagnosis and unnecessary 
treatment (Kalager et al, 2012).  
McCulloch et al. (2006) studied canines for both breast and lung cancer detection. They trained 5 
canines (3 Labrador Retrievers and 2 Portuguese Water Dogs aged 18 months – 7 years) over an 
unspecified duration to detect breast cancer on exhaled breath. Breath samples were collected from 
31 confirmed breast cancer patients (as soon as possible after biopsy, but prior to treatment 
commencement) and 83 volunteers with no previous cancer history (not age/symptom matched). It is 
worth noting that no details as to the time between biopsy and breath sample collection are reported. 
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There is no suggestion that the 83 control participants were suffering from any other non-cancer 
pathology however this is not clearly stated. These samples were collected in polypropylene sampling 
tubes obtained from Defencetek, South Africa and stored at room temperature for up to 60 days prior 
to analysis. A search into validation of these polypropylene sampling tubes revealed no information as 
to how long the sample can remain viable or about the best conditions to store them; since this 
appears to be a common technique throughout multiple canine studies validation of this technique 
would go some way to improving the reliability of such studies. However since at this stage the VOCs 
captured are unknown, developing a technique to validate this method of breath sampling is at best 
problematic. Furthermore this paper fails to report on how long the control samples were stored for 
and under what conditions; although a Fischer 2-sided exact test revealed “There was no statistically 
significant difference between patients and controls in the time from breath sampling to testing” 
(McCulloch et al, 2006). The reported result of P=0.52 for the Fischer 2-sided exact test is the only 
information provided to substantiate this quote, there is no reported method in this study for this 
calculation or explanation of how this conclusion was reached. Only 6 breast cancer patients (with 17 
controls) were used in testing; these yielded a sensitivity of 0.88 and specificity of 0.98 using a double 
blind method; both were found to be similar across all stages of disease. All breath samples sniffed 
during formal testing were from completely different subjects not previously encountered by the 
canines during training. Willis et al, 2011 demonstrated symptom matched controls can have a 
negative affect on canine performance. The absence of symptom matched controls by McCulloch et 
al, (2006) may therefore have contributed to the seeming success of this study (which is noted by the 
author).   
Breath VOC analysis with thermal desorption gas chromatography- mass spectrometry (GC-MS) by 
Phillips et al, (2006) identified: “2-propanol, 2,3-dihydro-1-phenyl-4(1H)-quinazolinone, 1-phenyl-
ethanone, heptanal, and isopropyl myristate” (Phillips et al, 2006) as potential biomarkers of breast 
cancer. In the discussion the author states the biological basis for production of these compounds 
remains elusive. These compounds were selected as potential biomarkers based on a subtraction 
chromatogram; VOC abundance in the ambient air was subtracted from the VOCs in the breath 
sample. Analysis was carried out using a fuzzy logic statistical program. While this is encouraging the 
paper does use only a small sample of 51 asymptomatic patients with abnormal mammogram results 
(cancer diagnosis later confirmed through biopsy) and 42 age-matched healthy controls. This test 
predicted breast cancer with 93.8% sensitivity and 84.6% specificity. The follow up study (Phillips et 
al, 2010) paid considerably more detail to both study design and statistical analysis. This study used 
54 patients with confirmed breast cancer (samples taken prior to treatment); and 204 cancer free 
controls. 1 Litre of breath and 1 litre of ambient air were collected on to sorbent traps; this allowed 
correction for any VOCs in the ambient air. The sensitivity (87.5%) and specificity (79.7%) were lower 
than that of the previous study, 30 volatiles were identified as potential markers of breast cancer, 
including: - cyclopropane ethylidene, tridecane, tetradecane, cyclotetrasiloxane octamethyl, and D-
Limonene. It worth noting the 5 potential biomarkers noted by this group in their pilot study (Phillips et 
al, 2006) was not mentioned in this later work. This paper postulates the activation of cytochrome 
P450 in breast cancer provides the basis for the variation in breath VOCs, the authors hypothesis 
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suggests a high-risk phenotype of cytochrome P450 increases the products associated with oxidative 
stress e.g. alkanes; thus increasing exhaled VOCs.    
Colorectal cancer  
Sonoda et al. (2011) used exhaled breath and stool samples for canine discrimination between 
patients with and without colorectal cancer. The canine was an 8-year-old black Labrador. Stool 
samples were obtained by suction during colonoscopy. The sensitivity using stool samples was 0.97 
and the specificity was 0.99. It is not stated if the same participants were used for both stool and 
breath collection or if a different cohort was used for each sample type.  Breath collection was 
performed by the participants exhaling approximately 100-200 millilitres of air into a breath collection 
bag obtained from Otsuka pharmaceutical company, Japan. These breath bags were placed into a 
zip-lock bag and stored at 4oC; a full exhalation (from beginning to end) was obtained. In a number of 
other studies, it is usually only the end volume of breath collected to avoid collecting breath from the 
alveolar ‘dead space’, the authors fail to allude why this was not the case in this instance. The 
sensitivity using breath samples was 0.91 and the specificity was 0.99. All control stool samples were 
taken from patients undergoing investigative colonoscopy, so controls were symptom-matched. 
During testing, samples not encountered previously by the canines were used, furthermore each test 
sample and control sample were only used once. For breath testing 33 patient samples and 132 
controls were used; for stool testing 37 patient samples with 148 controls were used. There is no 
information given as to how many samples were used for training, or how, when, and where the 
training samples were obtained. Accuracy was found to be high even for early-stage cancers, 
providing strong evidence for the possibility both breath and stool samples emit VOC patterns specific 
to colorectal cancer. This study performed the test trials during the winter/ spring months; the authors 
claim this is due to the canines lack of concentration during the warmer weather; this raises important 
questions as to the reliability of canines and affects of numerous external influences on canine 
behaviour though it should be noted the authors do not provide any evidence to support this claim.  
A 2013, study had success in identifying colorectal cancer with an accuracy of 75% using VOCs from 
exhaled breath, via GC-MS (Altomare et al, 2013). In this study breath was collected in Tedlar® bags 
from fasted participants, the participants also had to acclimatise to the room the breath was collected 
in for at least 10 minutes to create an equilibrium between ambient air and lung air; additionally the 
sampling procedure had undergone some validation work in a previous study (Dragonieri et al, 2007). 
Background VOCs from Tedlar® bag production such as N,N-dimethylacetamide were also considered 
before analysis took place. Sample collection details such as participant fasted status, ambient air 
conditions, and validation of technique are rarely reported in canine studies. Altomare et al, 2013, also 
showed that while no-one biomarker stood out; 58 VOCs were initially identified these were then 
whittled down by eliminating: background VOC from the Tedlar® bags, and infrequently occurring 
VOCs. The remaining VOCs were narrowed down further with a box plot. 15 VOCs remained as 
potential biomarkers, these included: - decanal, nonanal, 2-methylbutane, cyclohexane, 4-
methyloctane. These hydrocarbons and aldehydes could be due to oxidative stress. 
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Lung cancer  
Lung cancer is the commonest cancer in the UK. Currently there are no suitable options for the 
routine screening of lung cancer; therefore the development of an effective technique suitable for 
mass screening is greatly needed.  
McCulloch et al. (2006) trained 5 ordinary household canines (3 Labrador Retrievers and 2 
Portuguese Water Dogs aged 18 months – 7 years) to assess lung cancer detection on exhaled 
breath. Breath samples were collected from 55 confirmed lung cancer patients (as soon as possible 
after biopsy) and 83 volunteers with no previous cancer history (not age/symptom matched). As 
mentioned previously in this paper there is no suggestion that the 83 control participants were 
suffering from any other non-cancer pathology however this is not clearly stated. Moreover since 
there is no reported time frame between biopsy and breath collection it possible the breath VOC 
alterations may be a result of residual anaesthetic effects. Harrison et al (2003) demonstrated that it 
was possible to see metabolites of the anaesthetic propofol using proton transfer reaction mass 
spectrometry on exhaled breath. Thus in the McCulloch et al (2006) study, since the control 
participants had been anaesthetised it is possible the canines were distinguishing between 
anaesthetised and non-anaesthetised patients. 28 patient samples were used for the double blind 
testing phase of the trial along with 17 controls. A sensitivity and specificity of 0.99 was achieved, 
using a double blind method. The sensitivity and specificity was found to be similar across all stages 
of disease (this study has been discussed in this paper see breast cancer).  
Ehmann et al. (2012) trained four canines (two German Shepherds, an Australian Shepherd and a 
Golden Retriever) to detect lung cancer on exhaled breath. It was a large study with 220 participants, 
either healthy (n = 110), with histologically confirmed lung cancer (n = 60), or with chronic obstructive 
pulmonary disease (COPD) (n = 50). An overall mean accuracy of 73% and an overall sensitivity of 
0.71 and specificity of 0.93 were obtained. The inclusion of a COPD group allowed the authors to 
determine that in this study the canines appeared to be able to distinguish between lung cancer and 
COPD patients; this suggests each disease has its own unique odour. Moreover the lung cancer 
odour pattern was also detectable despite smoking status or diet of the patients. These results were 
obtained using a double blind method, and different breath samples were used during training and 
formal testing. These numbers at first inspection appear encouraging though it should be noted there 
was a considerable variability between individual canines with accuracy ranging from 68% to 84%. 
Unlike many other studies of this kind the authors have presented figures for PPV and NPV of 75% 
and 93% respectively. This study does contain significant detail regarding the methods employed 
however it does mention two separate sample collection sites; though there is no mention which 
samples were collected at which site. This study attempts to display canine odour recognition as a 
robust method and thus contains no participant restrictions such as diet or smoking status.  
More recently Amundson et al. (2014) tested the olfactory ability of 4 canines a Belgian Shepard, 
Boarder collie, Hard hair dachshund, and Rottweiler to detect lung cancer using exhaled breath and 
urine. Samples were taken from 93 patients admitted to hospital with suspected lung cancer; none of 
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the participants were healthy, 59 were diagnosed with lung cancer. Following low accuracy on an 
interim analysis, a period of “intensive training” (Amundson et al, 2014) was employed before a 
second block of testing was carried out; this simply involved doubling the weekly training sessions. 
The breath test samples were divided into two groups, the first group of 46 participant samples had an 
overall sensitivity of 64.7% (ranging from 67.6% to 61.8% for individual canines); and overall 
specificity of 8.3% (16.7% to 8.3% for individual canines). A period of intensive training followed 
before testing the next group of 40 patients. This second test yielded an overall sensitivity of 56% and 
specificity of 33.3% (ranges from 56% to 76% sensitivity for individual canines and 33.3% to 53.3% 
specificity). 77 urine samples were available from the same set of patients all samples were tested 
twice, again, with a period of intensive training between the first and second tests. The first test 
overall sensitivity and specificity were 73.6% and 25% respectively and 64.2% and 29.2% 
respectively for the second test. Individual canine sensitivity ranged from 49.1%- 71.7% across the 
two tests and specificity ranged 20.8%-41.7%.   
Rudnicka et al. (2014) investigated canine olfactory detection of lung cancer on exhaled breath 
alongside GC/MS analysis. Based on our search this is one of few instances in which analytical 
techniques such as GCMS have been employed in conjunction with canine testing. This approach 
would seem a logical step in identifying the distinct odour pattern the canines appear to be detecting. 
The GCMS analysis was used in conjunction with solid-phase micro extraction (SPME) pre-
concentration. Two male German Shepherds of unknown ages were used. This study used breath 
collected from 108 patients with confirmed lung cancer, 121 healthy controls and 24 controls with 
other respiratory disease. The canine sensitivity was reported at 0.86 and specificity 0.72 using a 
double blind method. Again, it is unclear whether any samples used during training were re-used 
during testing. GC-MS analysis yielded a sensitivity of 0.74 and a specificity of 0.73. The authors note 
several compounds found in significantly higher concentrations in samples from cancer patients than 
those from healthy controls; acetone, isoprene, ethanol, 1-propanol, 2-propanol, hexanal and dimethyl 
sulphide the authors deemed most noteworthy. Despite the promising canine figures again we see 
large variation between the two individual canines. There appears to be significant statistical analysis 
with positive and negative predictive rates being calculated. 
Melanoma  
Pickel et al. (2004) found two canines (a 4 year old Standard Schnauzer and 6 year old Golden 
Retriever) were able to differentiate melanoma (skin cancer) from controls, although sensitivity and 
specificity were not stated. This group conducted three separate trials, initially box trials were 
conducted where by the malignant sample was place in one of 10 wells, and the remaining wells were 
filled with materials such as latex gloves or gauze in order to distract the canine. The amount of filled 
wells varied from trial to trial and empty wells were not considered during results analysis. Canine A 
performed 16 box trials and canine B 11 box trials. It is not stated if the same malignant samples were 
used for both canines. In each case both canines performed with a 100% success rate. This 
prompted the beginning of the next round of testing in which malignant skin biopsies were placed on 
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the bodies of volunteers in sticking plasters. The placement of the plaster (sample) was varied each 
time, each dog was tasked with locating 5 samples each and again both gave 100% success rate. 
Both canines were then instructed to localize the melanoma source on 7 live patients, canine A 
correctly localized melanoma on six of the patients. Canine B sniffed 4 of the same patients (it is not 
stated why the remaining 3 weren’t tested on canine B), and correctly localised melanoma in three of 
the patients. The design of this study is questionable; melanoma tissue was placed on volunteers, 
which may not be relevant to live tumour detection; the authors suggest the VOCs emitted maybe 
from the underside of the removed tissue. Moreover tissue samples are known to deteriorate after a 
matter of hours and thus the canines maybe detecting VOCs associated with necrotising tissue. Dogs 
were also taken directly to a patient to sniff, which has been avoided by other studies. The results of 
this study are interesting but do not lend themselves as easily to potential screening applications. It is 
also unclear whether any test samples had previously been encountered by dogs during training. As 
is consistent with canine studies we again see variability in performance between individual canines.  
As seen with other cancers we again find some evidence that melanoma cells do exhibit an altered 
VOC signature compared to healthy cells. A study, once again, using SPME GCMS this time coupled 
with a single-stranded DNA coated nanotube sensor (DNACNT) was able to elucidate some VOC 
alterations in melanoma cells when compared to that of healthy melanocytes (Kwak et al, 2013). 
Although numerous VOCs differed between the two cell lines the team was able to identify two 
compounds (dimethyldisulfide and dimethyltrisulfide) unique to melanoma cells (Kwak et al, 2013).  
Ovarian cancer  
Ovarian cancer is the fifth most common cancer among women (Cancer Research UK, 2014); 
however it has a very poor prognosis, mainly owing to late detection (symptoms may be very similar 
to other conditions). Therefore developing an adequate method of screening is of great importance to 
affected individuals.  
Horvath et al. (2008) trained a 4 year old Riesenschnauzer to detect ovarian cancer from tissue 
samples. 31 different tumour samples were obtained and each one divided into 10-30 individual 
samples these were stored in a -80oC freezer and thawed for 15-30 minutes before use; all tissue 
samples were treated in the same manor (including controls). A number of different tests were 
conducted; single blind tests were conducted to determine if the canines could distinguish between 
ovarian cancer and healthy tissue. In this test tumour samples had been used during the training 
process (4 patient samples), the control samples were comprised of fat and abdominal muscle 
samples (unspecified quantity); in this case the canine achieved sensitivity and specificity of 1.0. In 
the following single blind test ovarian carcinoma tissue (from the same 5 patients as previous test) 
was used along side an unspecified number of non-ovarian gynaecological carcinomas. In this 
instance sensitivity was again 1.0 and specificity of 0.91 (the result of three false positives). For the 
double blind testing 20 new samples were used and had not been previously exposed to the canine; 
the controls (again unspecified amount) comprised of healthy muscle, fat and small bowel samples. In 
this instance the canine again achieved a sensitivity of 1.0 and a specificity of 0.975. The tumour 
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sample and control samples were kept in separate rooms, to avoid odour contamination; however this 
presents a potential flaw as it is possible the samples were contaminated with the ambient air and 
thus the canine may have been distinguishing the room the sample was prepared in.  Furthermore the 
controls used were not obtained from a gynaecological source but were in fact other tissue types such 
as small bowel, which may already containing differing odour patterns than healthy gynaecological 
samples.   
Tissue biopsies are invasive and unsuitable for routine screening; blood sample collection, however, 
is less invasive and a more promising option. Horvath et al. (2010) were able to use 2 Giant 
Schnauzers (aged 7 and 3) to detect ovarian cancer from blood samples, with a sensitivity of 1.0 and 
specificity of 0.98. Blood was collected from ovarian cancer patients before primary cancer surgery, 
and control blood was collected from healthy (mainly young) females and some male blood samples 
were used as controls (the authors report this did not effect canine performance). These samples 
were spun in a centrifuge, the collected plasma retained and frozen at -80 0C until required for testing. 
Different samples were used for training and testing; it is unclear how many patient and control 
samples were collected. It should also be noted that some of the controls used alongside the patient 
plasma were of differing tissue such as abdominal fat and other gynaecological tumour tissues e.g. 
cervical carcinoma. This study shows very little variation between the different canines, and seems to 
address a number of causes for concern in the previous study, Hovarth et al, 2008. The discussion 
raises the interesting point that the canine nose can only detect odour molecules whilst analytical 
techniques such as the electronic nose used in previous work by the team will potentially be able to 
detect non-odorous compounds such as methane. Conversely it is also possible the canine nose is 
more sensitive to certain compounds that may be beyond the detection range of an electronic nose.  
A recent pilot study however has used GCMS and a separate nanoarray of sensors to analyse breath 
samples of 182 participants (48 with ovarian cancer) (Amal et al, 2015). Although the results were not 
as good as those seen in the discussed canine studies the team achieved an accuracy, sensitivity 
and specificity of 71% and were able to identify several potential biomarkers including 2-butanone and 
hexadecane. The nanoarray technique performed considerably better with accuracy, sensitivity, and 
specificity of 0.89, 0.79, and 1.0 respectively. The obtained signals from the sensor array were used 
to build diagnostic classifiers with discriminant factor analysis. Using this method the nanoarray was 
able distinguish early from advanced cases of ovarian cancer (Amal et al, 2015).      
Prostate cancer  
Prostate cancer is the most common cancer among men in the UK (Cancer Research UK, 2014). The 
current standard screening method for prostate cancer is the prostate specific antigen (PSA) test. 
However it is only indicatory, not diagnostic.  PSA levels can be raised in other benign conditions, or 
may not be raised at all in some men with prostate cancer leading to false negatives (Catalona et al, 
1991). Therefore there is a real need for an alternative test.  
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Cornu et al. (2011) trained a Belgian Malinois to distinguish between the urine of 33 men with biopsy 
confirmed prostate cancer and urine from 33 controls, with a sensitivity and specificity of 0.91, 
generated from new samples in a double blind manner. A total of 108 urine samples were collected; 
26 cancerous samples and 16 controls were used during the training phase and the remaining 
samples used for testing. All participants had been referred with raised PSA levels and/or abnormal 
digital rectal examinations so were age/symptom matched, and urine was collected (and frozen) upon 
the first urologist consultation. After biopsy they were placed in the cancer or control category. 
Separate samples from different individuals were used for training (26 cancer samples and 16 control 
samples). It was hypothesised that the biochemical difference between the samples may be attributed 
to the presence of significantly increased levels of sarcosine in cancerous urine, as found by 
Sreekumar et al. (2009), however subsequent studies have failed to replicate these findings. The use 
of only one canine does limit this study (as mentioned by the author); furthermore samples were 
frozen at -4oC, for an unspecified time period compared to the more usual standard of -80C. This 
paper does describe in some detail the limitations of this kind of study, for instance the small sample 
sizes making real conclusions hard to define. The authors also raise the point the process of training 
and testing the canines is both expensive and lengthy, greatly limiting the potential for clinical 
application.      
A later study by Elliker et al. (2014) found that although two canines (a 9 year old Labrador and a 3 
year old Border collie) appeared to have learned to select for prostate cancer in urine samples during 
training, they did not select for prostate cancer when presented with new samples. The authors 
attributed lack of success to canine memory of control samples, which is of concern. 31 Patients with 
small to metastatic prostate cancer tumours and 93 controls (either healthy or with benign prostatic 
hyperplasia, information regarding the controls used during testing is sparse) took part in this study, 
which used a double blind design. 50 cancer samples and 67 control samples were used during 
training, and 31 cancer samples and 93 control samples were used during testing. Crucially this paper 
makes a unique point of noting that all samples (control and patient) were collected in the same place. 
This process aims to eliminate contamination of odours associated with the ambient air of clinical 
settings, though ideally to further enhance this process all samples should be collected at the same 
time. The authors also encounter difficulties in the variability of individual canines, which is reported in 
the majority of studies. Moreover the temperament of the canines meant that only three of the ten 
canines selected progressed past the first training stage due to either excitability or inability to 
motivate the canine to task. This paper highlights that in a number studies it is not stated whether 
during the testing phase (double-blind or otherwise) completely new patient/subject samples are used 
so that the dog has had no previous exposure to the samples in training. Once a dog has received 
training on a specific individual the dog will be conditioned to this person’s odour as a negative or 
positive sample. This means that if it is not stated that the patients and samples are completely new 
to the dog the results are likely to show an inflated sensitivity/specificity. Only results from papers that 
clearly state that patients and samples were completely new to the dog during testing can be 
considered reliable. 
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A very recent study by Taverna et al (2015) has provided very promising results. 2 3-year-old German 
shepherd canines were used to identify prostate cancer from urine. These canines had previously 
been trained in explosives detection; in this instance the canines underwent full time operant 
conditioning training to differentiate prostate cancer patients from controls. A total of 902 participants 
were recruited for this study. The cancer group consisted of 362 males split into 5 groups: group 1 
had been treated with surgery (n=180), group 2 had increased PSA and histological diagnosis of 
prostate cancer following biopsy (n=120), group 3 had prostate cancer detected incidentally (n=22), 
group 4 had metastatic prostate cancer or were receiving hormone therapy (n=29), and group 5 had 
primary prostate cancer and another tumour (n=11). Similarly the control group of 540 was also split 
into sub groups. 122 of the control participants were female, 50 of who were healthy and 72 of whom 
had non-neoplastic conditions. The use of controls of the opposite sex has been avoided in other 
studies as canines many be able to detect hormonal differences to differentiate male from female 
participants (Willis et al. 2004). If the canines are easily able to differentiate male from female 
samples this may this may partially increase the chance of the canine successfully identifying the 
correct sample. The authors state the use of female controls during the early testing phase prevented 
the canines from being confused by prostrate specific VOCs. The authors do go on to perform 
statistical analysis, which discounts the female controls. The remaining controls were split into 4 other 
groups including: healthy males, males 45+ years old with urological and/or systemic disease, urinary 
obstruction due to benign prostatic hyperplasia, and a group with low PSA and negative family history 
of prostate cancer with negative results of digital rectal exam and non-prostatic cancer. All urine 
samples were stored at -20oC and controls and patient samples were kept separately to avoid 
contamination. 200 patient samples and 230 controls were used for training and were not reused for 
testing; moreover all testing was performed in a double blind manor. The authors present the findings 
of the 2 canines separately and do not combine the results as many other papers do; this means the 
variability between the canines is transparent (and very low in this instance) and prevents inflation of 
overall results by averaging. Canine 1 achieved an overall sensitivity of 1.0 and specificity of 0.987 
(which dropped to 0.983 once excluding female controls and 0.98 when considering only controls of 
45 year old plus males). Canine 2 was only slightly inferior with an overall sensitivity of 0.986 and 
specificity of 0.976 (which dropped to 0.969 once excluding female controls and 0.964 when 
considering only controls of 45 year old plus males).        
As with ovarian cancer we again find sparse evidence to elucidate what VOCs are present in cases of 
prostate cancer. Smith et al, (2010) had some success in identifying VOC alterations in patients with 
prostate cancer. Additionally formaldehyde has also been postulated as a possible biomarker, though 
this is now somewhat outdated and doesn’t appear to have been brought to fruition (Spanel et al, 
1999).  
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Table 1.1 Comparison of canine studies 
 Cancer 
type 
Sample 
type 
Cancer 
stage 
Quoted 
Sensitivities/ 
specificities 
No. of 
canines/ 
breeds 
Participants/ 
participants 
with cancer 
Blinding Same 
samples 
used for 
training 
and 
tests 
Amunsdon 
et al. (2014) 
Lung Breath Not stated 0.618-0.676/ 
0.083-0.167 
Belgian Shepard, 
Boarder collie, 
Hard hair 
dachshund, and 
Rottweiler   
Not stated/ 93 Double 
blind 
Not 
Stated 
Cornu et al. 
(2011) 
Prostate Urine Not stated 0.91/ 0.91 1/ Belgian 
Malinois 
66/ 33 Double 
blind 
No 
Ehmann et 
al. (2012) 
Lung Breath Not stated 0.71/ 0.93 4/ 2 German 
Shepherds, 
Australian 
Shepherd, 
Golden Retriever 
220/ not stated Double 
blind 
No 
Elliker et al. 
(2014)  
Prostate Urine Small to 
metastatic 
tumours 
Not stated 1/ Labrador, 
Border Collie 
124/ 31 Double 
blind 
No 
Horvath et 
al. (2008) 
Ovarian Tissue Borderline 
to 
metastatic 
tumours 
1.0/ 0.98 1/ 
Riesenschnauzer 
Not stated/31 Single 
and 
double 
blind 
No 
Horvath et 
al. (2010) 
Ovarian Tissue Borderline 
to 
metastatic 
tumours 
1.0/ 0.98 2/ Giant 
Schnauzers 
Not stated Double 
blind 
No 
McCulloch 
et al. (2006) 
Lung and 
breast 
Breath Range of 
disease 
stages 
0.99/ 0.99 for 
lung cancer 
0.88/ 0.98 for 
breast cancer 
5/ 3 Labrador 
Retrievers, 2 
Portuguese 
Waterdogs 
169/ 86 Double 
blind 
No 
(breast) 
No (Lung) 
Pickel et al. 
(2004) 
Melanoma Tissue Not stated Not stated 2/ Standard 
Schnauzer, 
Golden Retriever 
Not stated/ 7 Double 
blind 
Not 
Stated 
Rudnicka et 
al. (2014) 
Lung Breath Not stated 0.86/ 0.72 2/ German 
Shepherds 
253/ 108 Double 
blind 
Not 
Stated 
Sonoda et 
al. (2011) 
Colorectal Breath 
and 
stools 
Range of 
stages 
0.91/ 0.99 for 
breath 0.97/ 
0.99 for stools 
1 /Labrador 350/ 70 Not stated No 
Taverna et 
al. (2015)  
Prostate Urine Very early 
to 
metastatic 
tumours 
 Canine 1 1.00/ 
0.987- 0.98 
Canine 2 
0.986/ 0.976-
0.964 
2/ German 
Shepherds 
540/ 362 Double 
blind 
No 
Willis et al. 
(2004) 
Bladder Urine New or 
recurrent 
carcinoma  
41% success 
rate  
6/ not stated 144/ 36 Single 
blind  
No 
Willis et al. 
(2011) 
Bladder Urine Not stated 0.64/ 0.56- 
0.92 
4/ not stated 210/ 30 Double 
blind 
No 
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 Overview 
Canines are reported to have been assessed for their ability to differentiate cancers from healthy 
controls, and are summarised in Table 1.1, along with the values obtained for sensitivity and 
specificity. The most notable feature of Table 1.1 is the amount of “not stated” values; omissions of 
key facts, particularly in methodology, calls into question the validity of the produced statistical values. 
Although the levels of detection have, in some cases been remarkably high and superior to the 
current commercial tests (e.g. PSA test for prostate cancer).  
A review paper by Horvath et al. (2009) reported on several analytical methods of detecting lung 
cancer biomarkers including SPME-GC, GCMS with sorbent trap, electronic noses, and canine 
olfaction, and found that canine olfaction achieved sensitivity and specificity superior to any other 
method (0.99, found by McCulloch et al., 2006). Though there are significant limitations and questions 
to be raised by the McCulloch et al, 2006 study which have been discussed (see section headed 
breast cancer). Furthermore since all the techniques discussed in the Horvath et al. (2009) review are 
highly variable (in terms of sample collection and processing, and pre-concentrating methods) 
comparison of these methods against one another is inappropriate. 
The cancer diagnoses in canine studies have typically been confirmed by gold standard biopsy 
(followed by microscopy). It should be considered though that canine detection is very much a 
positive/ negative test as communication of quantification of odour patterns from canine to human 
would be highly subjective (if at all possible). Thus the canine “diagnosis” could not be considered for 
prognosis or treatment response measurement, both of which are critical to an effective biomarker. 
Moreover studies haven’t been large enough to undertake rigorous statistical analyses with the 
majority of studies simply quoting sensitivities and specificities; while these figures are of great 
importance to a diagnostic test they are just two of multiple factors contributing to the effectiveness of 
a test. As Cornu et al (2011) remarked the process of training and testing the canines are both time 
consuming and costly. That said, once a canine has been trained the testing process is very rapid; 
once presented with a sample(s) the canines in the above studies are able to make a decision within 
seconds as noted by Cornu et al (2011) (quoted a mean time of 30 seconds). For comparison the run 
time for a sample with the GCMS method used by Rudnicka et al (2014) took in excess of thirty 
minutes; this does not include time to condition the equipment before sample collection and pre-
concentrating can take place. 
Clearly for a good robust canine study, age-matched and symptom-matched controls are required. 
These may be patients with benign illness, whose symptoms triggered them to seek clinical 
investigation, e.g. Amundson et al. (2014) controls had been admitted to hospital with suspected lung 
cancer, and subsequently found to be negative for the disease. In the majority of the studies 
commented upon here a mix of healthy and symptom matched controls are used; these often include 
benign tumour samples. However, it is sometimes the case that only ‘healthy’ individuals have been 
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used as controls. When using symptom matched controls it is not possible to know for certain if the 
individual is cancer free or subject to a false-negative test result. For example the study by Cornu et 
al. (2011); in which control samples were collected from patients that had abnormal levels of PSA and 
abnormal digital rectal examination (DRE); found during testing three of these controls were identified 
as positive by the canine all three patients had a second biopsy; one of these was confirmed as 
having prostate cancer. Studies, which have selected age-matched and symptom-matched controls, 
do show lower levels of sensitivity (e.g. Amundson et al., 2014), indicating that the task becomes 
more difficult as the level of ‘noise’ increases, making the cancer signature harder to detect. It should 
be noted however this is often the case for more traditional analytical studies and is not a problem 
exclusive to canine detection. 
A potentially confounding factor in studies using breath samples is the site at which samples are 
collected; ideally samples should be collected from individuals in similar environments at the same 
time of day, or preferably all samples should be taken in one session; though in reality this is unlikely 
to be feasible. For example, if diseased (cancer) samples are taken from patients in a hospital 
environment and control samples are not collected in a clinical setting, it is possible that hospital 
volatiles may be present and improve dogs’ performance. The papers reviewed do not clearly state 
where samples were collected, which should be addressed in future studies. Ideally both patient 
samples and controls should be collected in a non-clinical setting to prevent clinical ambient VOCs 
contaminating the healthy controls. Since this scenario is often not possible, as some patients will 
have no option but to be in a clinical setting, control participants should therefore be invited to the 
same clinic as the patients (though this remains suboptimal since ambient VOCs also vary with time).  
Storage and collection of breath samples also have inherent complications. Most canine studies 
collect breath using oil coated polypropylene fibres in a plastic tube, which the participant then 
breath’s over (usually 3 deep exhalations, as in Rudnicka et al, 2014). This means the quantity of air 
passing over the fibres will be highly variable between participants, particularly for use in lung cancer 
testing, it may in this instance be a lack of odour the canine is responding to. Furthermore the study 
by McCulloch et al, (2006) kept breath samples in a sealed plastic bag for up to 60 days without 
providing any validation work to ascertain the viability of the samples over time. Our own search into 
validation of this breath sampling technique also yielded no results despite this method being 
commonly used in canine studies and for forensic applications. The collection, handling and storage 
of ‘hard’ samples (blood, urine, and stool) tend to be standardised in that very soon after collection 
these samples are frozen at -80oC or in some cases -20oC until defrosting for use. Once thawed these 
samples are often warmed to body temperature (37oC) and used within an hour. 
Perhaps the most important issue faced by canine studies is the amount of variability between 
individual animals. This may contribute to the seemingly high success rates in studies only using one 
canine. The study by Ehmann et al (2012) highlights this point well with their canines demonstrating 
an accuracy varying between animals of 0.68- 0.84. By averaging out these results or only reporting 
the upper figures it is to see how some studies might show artificially high results. The reason for the 
variability has been commented upon in Cornu et al (2011), which cites “olfactory-receptor 
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polymorphisms” (Cornu et al, 2011) as the cause. There is evidence to suggest the G- allele on the 
cOR9S13 gene can have a positive effect on binding affinity of some odour molecules to olfactory 
receptors (Lesniak et al, 2008). This points the way to suggest that genetic studies may pave the way 
for the efficient selection of canines in cancer odour studies. There is also the possibility to use this 
knowledge to develop biosensor technology, where by grown cells with these genes can be utilised 
for their binding affinities.   
Furthermore, in order for canine detection to be clinically useful, studies will need to be done on the 
canine’s performance over time. The studies reported in this paper do not give an accurate 
description of the time lapse between training and testing; though it is likely this is a short time period. 
Should the canine require constant training to maintain performance this will significantly increase the 
overall costs of testing and reduce the possible efficiency of testing sites. Canines will also have to be 
selected based on behaviour patterns as Elliker et al. (2014) eluded to; in this instance only three of 
the ten originally selected canines showed the necessary behaviour to progress past the first round of 
training. This again could significantly raise the overall costs associated with this type of testing.    
An option to introduce the clinical utility of canines might be to collect samples in the clinic, and 
transport them to specialist screening centres, using carousel systems and stands, such as those 
used by APOPO rats for tuberculosis detection, or the RASCargO™ system, used for canine 
detection of explosives in cargo. Potentially thousands of samples could be screened in this way. 
Information could then be sent to the clinician to be added to the whole picture, before being 
discussed with the patient; importantly the canine does not diagnose but simply provides an additional 
test result. Though this approach will detract from the appealing rapidity of canine testing by adding 
significant time between sample collection and receiving a result; thus in order to make this a cost 
effective solution reliability of results must be significantly improved. 
Recommendations for future canine studies 
In order improve the reliability of reported findings in canine studies a number of key areas need to be 
addressed and implemented across the field.  
Sample collection and storage 
1. Breath sample storage media for use in canine studies (polypropylene fibres as in McCulloch 
et al, 2006) should undergo rigorous validation study. This should set out the most 
appropriate storage of sample tubes and set time limits the samples should be used by; in 
addition to being made readily available for reference.  
2. All breath samples should ideally be collected in the same room; including controls as in 
Elliker et al. (2014). This process will go some way eliminate the potential contamination of 
the sample with ambient air volatiles. Though as mentioned this is still not perfect as ambient 
VOCs can alter over time. 
3. Tissue, urine, and stool sampling have a well-defined collection and storage procedure. In this 
instance samples should be chilled immediately after collection to prevent degradation effects 
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such as tissue necrosis and urine alterations. Storage over longer periods of time (as is often 
required for such studies) should ideally take place in -80oC freezers. If samples are collected 
from patients under anaesthesia then conventional analysis should be undertaken to ensure 
no residual VOCs from the anaesthesia remain.  
4. Once frozen samples are thawed and warmed to 37oC they should ideally be used within 2 
hours to prevent microbial growth from interfering with VOC emissions.  
5. Whole blood samples should be collected in EDTA vacutainers to stabilise folate, stored at 
4oC and used within 7 days, if analysis cannot take place in this time frame again -80oC 
freezer storage is required (Tolonen et al, 2002).   
6. Detailed information on sample handling, storage and usage should be reported in all 
publications including reference material of validation studies. 
Participants 
1. Inclusion and exclusion criteria for both controls and participants should be reported. 
2. Controls should be sex matched to prevent hormonal interference (Willis et al. 2004). 
3. Controls should include symptom matched non-cancerous samples to ensure the canine is 
not simply differentiating between healthy and non-healthy. 
Training 
1. There should be an agreed upon best practise training methodology used across the field. It 
is worth noting all the studies in this report use broadly speaking the same training procedure. 
2. Detailed reporting of all methodologies employed should be included in publications. Including 
detailed information regarding the collection, storage, and quantity of samples used over the 
training duration. 
Testing 
1. All testing procedures should be thoroughly detailed in publications. 
2. Crucially samples used in training must not be used in testing; all new samples are required 
for all tests, both patient and control. 
3. Double blind method of testing should take place to prevent experimental bias. 
Analysis 
1. Clinical utility analysis should take place including PPV and NPV in addition to sensitivity and 
specificity. Canine studies usually only use small sample sizes, thus a detailed analysis is 
impractical and of limited value. 
2. Where an ROC curve is drawn the procedure with which the author derives this should be 
included in publication. 
Other points to consider 
18 
 
1. Individual canine results and the affect the variability between individuals has on the overall 
accuracy of the study should be reported in detail. 
2. The longer-term effectiveness of training should be assessed. Can the same training method 
be employed to maintain the canine’s efficiency? Additionally a full cost effectiveness 
evaluation should be conducted in order to ascertain any potential commercial viability. 
3. Where possible laboratory analysis (using appropriate method e.g. GC-MS) of the same 
samples should be done in conjunction with canine testing. In addition to validating the canine 
test this could also provide insight into potential biomarkers.   
Closing remarks 
Taken together the evidence presented by the work reviewed in this report does suggest there is a 
basis for the hypothesis that the canine olfactory sense (once trained) is sufficiently sensitive as to 
differentiate cancerous from non-cancerous samples. However the outlined concerns must be 
addressed before more substantial conclusions can be reached. Furthermore there needs to be larger 
studies performed that can under go the rigorous statistical tests necessary to validate the claims 
made. Given the variability between individual canines it is highly unlikely that canine detection could 
ever be used in a clinical setting. Moreover canine testing will not be able achieve the consistent 
levels of control compared to that of a laboratory investigation. 
Although some of the experimental design in canine studies can be called into question the same 
criticism can also be levelled at many analytical studies. One major advantage of many canine studies 
is that they incorporate both a model building (training) and true validation stage, where new patients 
are assessed by the trained canines. Admittedly this is an area which could be made more 
transparent within the studies so it is possible to determine the numbers used for both training and 
validation (and the number of patients retested from within the training set). However, many analytical 
studies identifying biomarkers of disease do not validate the statistical models on any samples 
outside the original patient cohort.   
The primary benefit of canine investigations is the encouragement that it gives to the volatile analysis 
community, to search for biomarker compounds or VOC patterns detectable by man-made volatile 
analysis systems; such as those reported.  
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